ITUS Followup Notes

I had a follow-up call with Dr. Kumar, CEO of ITUS, today. Basically, I was looking to understand more about the benign versus cancerous...

ITUS Corporation Announces First Commercial Focus for Cchek™ will be Prostate Cancer

Tailwinds' Take: ITUS has a potentially game-changing diagnostic here. Dr. Kumar's comments about benign studies are quite foreshadowing. We can expect to hear more...

No Doldrums For ITUS, Instead a Busy Summer Awaits

Last month Grail Inc. raised $300 million in a Series C equity financing. This brings their total raised to around $1.5B over the last...

Digging Deeper Into ITUS: an Interview with CEO, Dr. Amit Kumar

In a big week for ITUS, the Company announced outstanding results on a study undertaken with Memorial Sloan Kettering Cancer Center (MSK) and Serametrix,...

ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study

Tailwinds' Take: amazing endorsement of ITUS' Cchek technology by the premier cancer center. Cchek appears to have the potential to completely disrupt cancer diagnostics. SAN...

ITUS Announces Issuance of Second Key Cancer Detection Technology Patent

Tailwinds' Take: as ITUS continues to show clinical success on Cchek, protecting the IP will be critical to maintaining the incredible TAM. ITUS' patent...

ITUS to Present Data from Early Cancer Detection Study Utilizing Artificial Intelligence at the...

SAN JOSE, Calif., March 16, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), today announced that it will present the latest data from its ongoing early...

ITUS will Present Data at the American Association of Cancer Research (AACR) Annual Meeting

SAN JOSE, Calif., March 12, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), today announced that it will present data from its ongoing study utilizing Cchek™,...

ITUS: Implications of the Serametrix Partnership

On March 5th, ITUS announced an alliance with Serametrix Corporation in which the power of Cchek™ would be paired with Serametrix’s substantial expertise in...

ITUS Corporation Forms Alliance with Serametrix Corporation

Tailwinds' Take: Serametrix has a substantial volume of MDSC testing results, both historical and ongoing, on which Cchek can be evaluated. My guess is...

ITUS, CEO Update Interview

Last week, ITUS reported data on a study of their novel cancer diagnostic, C-Chek. I had the opportunity to check in and discuss this...

ITUS Presents Positive Data from its Early Cancer Detection Technology at ASCO-SITC Symposium

SAN JOSE, Calif., Jan. 29, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), today announced that it presented positive data from its early cancer detection technology...

ITUS, the Implications of ASCO-SITC

Later today, ASCO will release ITUS's abstract for the ASCO/SITC meeting. Investors have been anxiously awaiting the data from the presentation. However, the release of...

ITUS Will Present Early Cancer Detection Data at ASCO-SITC Symposium on January 26

Tailwinds' Take: to date, all data on C-Chek has been positive and there's no reason to expect anything different if they have been accepted...

Previewing 2018…What to Expect From Our Portfolio

As we enter the new year it is very difficult not to be optimistic...borderline exuberant. The Tailwinds Select Portfolio has been on a tear...

ITUS Corporation Terminates At-The-Market Offering

Tailwinds' Take: I love it when companies decide not to dilute their investors. ITUS' model is one of partnerships and joint-ventures. This is very...

ITUS Receives Notice of Allowance for Second Key Cancer Technology Patent

SAN JOSE, Calif., Nov. 28, 2017 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), a company using the power of the immune system to diagnose and treat...

ITUS: an Exciting Cancer Story, Part 2(b)

On November 13, ITUS Corporation announced that they had licensed a cancer therapy from the Wistar Institute, a Philadelphia based biomedical research organization. In doing...

ITUS Enters CAR-T Research Alliance with Moffitt Cancer Center

Tailwinds' Take: this is a big deal for ITUS as Moffitt is one of the preeminent cancer research centers in the US and their...

What Is A.I.??? And, Four Ways To Invest In It.

In the twenty-first century, AI techniques have experienced a massive surge in interest following concurrent advances in computer power, large amounts of data, and theoretical understanding....